Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Subanesthetic ketamine doses have been shown to have rapid yet transient antidepressant effects in patients with treatment-resistant depression, which may be prolonged by repeated administration. The purpose of this study was to evaluate the antidepressant effects of a single ketamine infusion, a series of repeated ketamine infusions, and prolongation of response with maintenance infusions. METHODS: Forty-one participants with treatment-resistant depression completed a single-site randomized double-blind crossover comparison of single infusions of ketamine and midazolam (an active placebo control). After relapse of depressive symptoms, participants received a course of six open-label ketamine infusions administered thrice weekly over 2 weeks. Responders, classified as those participants who had a ≥50% decrease in their scores on the Montgomery-Åsberg Depression Rating Scale (MADRS), received four additional infusions administered once weekly (maintenance phase). RESULTS: Compared with midazolam, a single ketamine infusion elicited a significantly greater reduction in depressive symptoms at the primary efficacy endpoint (24 hours postinfusion). Linear mixed models revealed cumulative antidepressant effects with repeated infusions and doubling of the antidepressant response rate. Fifty-nine percent of participants met response criteria after repeated infusions, with a median of three infusions required before achieving response. Participants had no further change in MADRS scores during weekly maintenance infusions. CONCLUSIONS: Repeated ketamine infusions have cumulative and sustained antidepressant effects. Reductions in depressive symptoms were maintained among responders through once-weekly infusions. These findings provide novel data on efficacious administration strategies for ketamine in patients with treatment-resistant depression. Future studies should further expand on optimizing administration to better translate the use of ketamine into clinical settings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ketamine, an NMDA glutamate receptor antagonist, reduced suicidal ideation within 1–4 hours in major depression(71–75) and bipolar disorder.(76, 77)”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [75]
In the citing paper
“Maintenance regimens extend benefit for some patients but only partially offset this erosion [82,83,84].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [84]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Inclusion criteria were a score $25 on the Montgomery-Åsberg Depression Rating Scale (MADRS) (21) at screening and at randomization, with no more than 20% improvement between these visits.”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 2×
“Self Report (QIDSSR) (24).”
MethodA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 3×
“Other studies that have employed a parallel design and reported higher response rates to single ketamine infusions have also reported notable response rates with midazolam, ranging from 11% (7) to 28% (5).”
BackgroundResultDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 6×
“CADSS scoreswere analyzed with paired t tests and Pearson’s correlation coefficient.”
MethodInfluentialZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 1×
“Although the antidepressant effects of ketamine become evident within a few hours or 1 day of a single infusion, the benefits generally disappear within 1 week (3).”
BackgroundA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576 · cited 2×
“Subanesthetic doses of intravenous ketamine have been shown to elicit rapid, albeit transient, reductions indepressive symptoms inpatientswith unipolar and bipolar depression (2).”
BackgroundSingh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 1×
“There have been reports of an association between dissociative side effects and antidepressant response to ketamine (28, 29).”
BackgroundShiroma, P. R., Johns, B., Kuskowski, M., Wels, J., Thuras, P., Albott, C. S., & Lim, K. O. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.036 · Cited by 221 · cited 1×
“(16), with more than three-quarters of study participants requiring three or more infusions before meeting response criteria.”
BackgroundNiciu, M. J., Shovestul, B. J., Jaso, B. A., Farmer, C., Luckenbaugh, D. A., Brutsche, N. E., Park, L. T., Ballard, E. D., & Zarate, C. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.049 · Cited by 132 · cited 1×
“There have been reports of an association between dissociative side effects and antidepressant response to ketamine (28, 29).”
BackgroundCusin, C., Ionescu, D. F., Pavone, K. J., Akeju, O., Cassano, P., Taylor, N., Eikermann, M., Durham, K., Swee, M. B., Chang, T., et al. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416631828 · Cited by 111
Continuation phase intravenous ketamine in adults with treatment-resistant depression
Voort, J. L. V., Morgan, R. J., Kung, S., Rasmussen, K. G., Rico, J. A. Q., Palmer, B. A., Schak, K. M., Tye, S. J., Ritter, M. J., Frye, M. A., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.008 · Cited by 101
Wilkinson, S. T., Katz, R. B., Toprak, M., Webler, R., Ostroff, R. B., & Sanacora, G. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11731 · Cited by 91 · cited 1×
“(13) recently provided preliminary evidence of the safety and tolerability of long-term ketamine administration, which mirrors our own clinical experience.”
BackgroundFrye, M. A., Blier, P., & Tye, S. J. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000316 · Cited by 75 · cited 1×
“On infusion days, participants were required to abstain from consuming grapefruit juice (a potent 3A4 cytochrome inhibitor that may slow the elimination of midazolam and possibly ketamine) (22) and to avoid taking any benzodiazepines the preceding day, as they attenuate ketamine response (23).”
BackgroundSelf-citationS-ketamine concentrations are greatly increased by grapefruit juice
Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Laine, K., Neuvonen, P. J., & Olkkola, K. T. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1214-9 · Cited by 32 · cited 1×
“On infusion days, participants were required to abstain from consuming grapefruit juice (a potent 3A4 cytochrome inhibitor that may slow the elimination of midazolam and possibly ketamine) (22) and to avoid taking any benzodiazepines the preceding day, as they attenuate ketamine response (23).”
Background
Research works printed but not linked: 7
- World Health Organization, 2016, Global Health Estimates 2015: Burden of Disease by Cause, Age, Sex, by Country and by Region, 2000–2015
- Fava M, Mol Psychiatry
- Sos P, 2013, Neuroendocrinol Lett, 34, 287
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
- Sackeim HA, 2001, J Clin Psychiatry, 62, 10
- Levine J, 1986, Psychopharmacol Bull, 22, 343
- Post RM, 2008, Treatment of Bipolar Illness, 123
Cited by
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060864 · Cited by 655
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
“Mean age Formulation Dose Scale Comparator Phillips 2019 (Phillips et al., 2019) Crossover TRD MDD 43 55.8 41.7 Racemic, adjunctive 0.5 mg/kg IV, single MADRS Midazolam Ionescu 2019 (Ionescu et al., 2019) Parallel TRD MDD 26 38.5 45.4 Racemic, adjunctive 0.5 mg/kg IV, multiple HDRS Placebo Popova…”
InfluentialBlinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Self-citation
Metadata
- Authors
- Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P.
- Affiliations
- University of Ottawa (CA)
- Venue
- American Journal of Psychiatry
- Published
- 2019-05-01
- Volume
- 176
- Issue
- 5
- Pages
- 401-409
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2935676591
- Cited by
- 418
- References
- 21
- Citations by year
- 2026: 33 · 2025: 46 · 2024: 67 · 2023: 66 · 2022: 58 · 2021: 72 · 2020: 56 · 2019: 19
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (274324)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, treatment-resistant depression, antidepressant response, relapse
- MeSH terms
- Adult, Ambulatory Care, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Humans, Infusions, Intravenous, Ketamine, Male, Midazolam, Middle Aged, Remission Induction, Treatment Outcome, Excitatory Amino Acid Antagonists, GABA Modulators, Maintenance Chemotherapy, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.